-
RXi Pharmaceuticals Strengthens NeuVax Patent Portfolio
Wednesday, July 13, 2011 - 7:06am | 112RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax™ (E75). The patents licensed from The Henry M. Jackson Foundation for the Advancement of Military Medicine,...
-
Morgan Stanley Provides Color on Baxter
Wednesday, July 13, 2011 - 6:30am | 162Morgan Stanley provided color on Baxter (NYSE: BAX). In a research report published today, the rating agency commented on Biogen's (NASDAQ: BIIB) new product, which does not seem to be threatening Baxter's products in the same field. In the report, Morgan Stanley states, “New pharmacokinetic data...
-
Piper Jaffray Reiterates Overweight and PT of $62 on Regeneron Pharmaceuticals
Wednesday, July 13, 2011 - 6:11am | 48Piper Jaffray reiterated its Overweight rating on Regeneron Pharmaceuticals (NASDAQ: REGN). At the same time, the rating agency left its price target on the company's stock unchanged at $62. On Tuesday, Regeneron lost 0.71% of its value to finish the day at $57.15.
-
Brean Murray Initiates InterMune At Buy, $50 PT
Wednesday, July 13, 2011 - 6:01am | 26Brean Murray Carret & Company has initiated coverage on InterMune (NASDAQ: ITMN) with a Buy rating and $50 price target.
-
ISI Provides Color on Biogen Idec
Wednesday, July 13, 2011 - 3:29am | 99ISI provided color on Biogen Idec (NASDAQ: BIIB). In a research report published today, ISI is optimistic about the company's new drug, which has the potential of outperforming its competitors. In the report, ISI states, “Abstracts for the ISTH meeting are out. For BIIB, the most important is the...
-
Stocks to Watch for Wednesday 07/13/11: Fresh 52 Week Highs and Lows
Tuesday, July 12, 2011 - 8:24pm | 1637Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Tuesday's trading session (listed from highest total volume to lowest): 1) Adventrx Pharmaceuticals (NYSE: ANX...
-
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Tuesday, July 12, 2011 - 4:07pm | 149Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from Phase 2b trials in rheumatoid arthritis and ankylosing spondylitis with sarilumab (REGN88/SAR153191), a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the...
-
Anadys Pharmaceuticals Jumps on High Volume
Tuesday, July 12, 2011 - 1:52pm | 111Shares of Anadys Pharmaceuticals (NASDAQ: ANDS) are popping hard this afternoon on high volume. Currently, shares are higher by 10.05%, trading at $1.09. Share volume is running at 911,000 shares; the 10-day daily average volume is only 123,000 shares. There is currently no new news for Anadys...
-
UPDATE: Hearing Positive Chatter Circulating in Anadys Pharma on Upcoming Phase II Results
Tuesday, July 12, 2011 - 1:31pm | 123@BioRunUp posts "$ANDS Poised for Rebound, Run-Up into Phase 2 Results for Pair of HCV Drugs" Also, @ProphetAlerts writes "$ANDS rippp ... catalysts coming for this bad boy. 6 months ago it went from .90 to $1.50 in a few days." Anadys Pharmaceuticals (Nasdaq: ANDS), on December 1st, announced...
-
Bank of America Merrill Lynch Discusses Seattle Genetics After FDA Briefing
Tuesday, July 12, 2011 - 12:28pm | 165Bank of America Merrill Lynch is out with a research report on Seattle Genetics (NASDAQ: SGEN) following comments from an FDA briefing. It has a Buy rating and a $22 price target on shares. In a note to clients, Bank of America Merrill Lynch writes, "The FDA released this morning briefing...
-
Jefferies Says Buy Seattle Genetics
Tuesday, July 12, 2011 - 12:24pm | 112Jefferies & Co. has a Buy rating and a $22 price target on shares of Seattle Genetics (NASDAQ: SGEN). In a note to clients, Jefferies & Co. writes, "We are encouraged that the FDA briefing documents for Adcetris are benign on key efficacy and safety analyses. We would be buyers of the...
-
Biotech/Pharma Trading Alert for BioSante Leerink Swann Initiates Analyst Coverage with $6.00 per share Fair Value
Tuesday, July 12, 2011 - 12:14pm | 1048Point Roberts, WA, LINCOLNSHIRE, Ill - July 12, 2011 - Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for July 11 th. The stock traded as high as $3.90 on over...
-
NASDAQ Top Movers; Kandi, YRC, Coffee Holding, Pluristem
Tuesday, July 12, 2011 - 12:00pm | 471POINT ROBERTS - July 12, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 11, 2011. Kandi Technolgies Corp. (NASDAQ: KNDI) soared 19.68% to $2.19 after the company said that it has signed an agreement...
-
C.K. Cooper Reiterates Isoray Buy, $2 PT
Tuesday, July 12, 2011 - 10:27am | 81C.K. Cooper & Company reiterated its Isoray (NYSE: ISR) Buy rating and $2 price target in a research report published today. In the report, C.K. Cooper states, "IsoRay reported Q3-2011 and has issued a number of news releases over the past few months worth noting regarding Cesium use in the...
-
Morning Market Movers
Tuesday, July 12, 2011 - 9:47am | 118Radiant Systems Inc (NASDAQ: RADS) climbed 30.35% to $27.96 at 9:45 am. NCR Corp agreed to buy RADS for $1.2 billion in cash. IsoRay Inc (AMEX: ISR) jumped 15.32% to $1.28. ISR shares have dropped 20.14% over the past 52 weeks, while the S&P 500 index has gained 22.32% in the same period....